Ricardo Anaya, President of the opposition National Action Party, has called for the pharmaceutical sector in Mexico to be opened to greater competition in order to reduce the price of medication. He added that the party will propose two actions: the first, to strengthen the powers of the Federal Competition Commission (COFECE), and second, to pressure authorities to “tighten their grip” against abuses, hoping to stop the rising costs of healthcare and medication.
Featured News
NBA Teams Up With US Regulator on Prediction Markets
Oct 27, 2026 by
CPI
Intesa Wins ECB Approval for $36 Billion Monte dei Paschi Takeover
Oct 27, 2026 by
CPI
PayPal, Revolut Weigh In as UK Targets Apple’s Tap-to-Pay Rules
Oct 27, 2026 by
CPI
Heineken Ordered to Pay $124 Million in Greek Antitrust Case
Oct 27, 2026 by
CPI
FTC Raises Antitrust Concerns Over Cintas’ $5.5 Billion Deal
Oct 27, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Exclusive Dealing
Oct 25, 2026 by
CPI
Exclusive Dealing Without Exclusivity: Screening Contracts, Loyalty Rebates, and the Limits of Antitrust Tests
Oct 25, 2026 by
David Martimort & Jérôme Pouyet
When Competition for Exclusivity Raises Prices: Rebates, Pricing Rules, and the Insulin Puzzle
Oct 25, 2026 by
Daniel P. O’Brien & Greg Shaffer
Why Leaving the Door Open Can Be (Much) Worse Than Closing It: Share-Based Requirements, Buyer-Specific Costs, and Foreclosure
Oct 25, 2026 by
Zhijun Chen & Greg Shaffer
Antitrust Chronicle® – EU Merger Guidelines
Oct 19, 2026 by
CPI